home / stock / oric / oric quote
Last: | $9.49 |
---|---|
Change Percent: | 1.71% |
Open: | $9.29 |
Close: | $9.33 |
High: | $9.54 |
Low: | $9.29 |
Volume: | 44,127 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.49 | $9.29 | $9.33 | $9.54 | $9.29 | 44,127 | 05-02-2024 |
$9.33 | $8.83 | $9.33 | $9.65 | $8.8 | 762,455 | 05-01-2024 |
$8.83 | $8.14 | $8.83 | $9.26 | $8.14 | 761,332 | 04-30-2024 |
$8.23 | $8.11 | $8.23 | $8.56 | $8.11 | 425,342 | 04-29-2024 |
$8.07 | $7.73 | $8.07 | $8.13 | $7.73 | 401,565 | 04-26-2024 |
$7.67 | $7.94 | $7.67 | $7.94 | $7.62 | 636,172 | 04-25-2024 |
$8.08 | $8.79 | $8.08 | $8.801 | $8.07 | 374,832 | 04-24-2024 |
$8.77 | $8.72 | $8.77 | $9.11 | $8.6705 | 270,384 | 04-23-2024 |
$8.72 | $9.27 | $8.72 | $9.43 | $8.67 | 315,162 | 04-22-2024 |
$9.19 | $9.35 | $9.19 | $9.4 | $8.72 | 668,037 | 04-19-2024 |
$9.51 | $9.98 | $9.51 | $10.03 | $9.35 | 589,783 | 04-18-2024 |
$9.76 | $9.58 | $9.76 | $10.03 | $9.43 | 509,942 | 04-17-2024 |
$9.45 | $9.44 | $9.45 | $9.7 | $9.33 | 203,765 | 04-16-2024 |
$9.54 | $9.78 | $9.54 | $9.95 | $9.34 | 332,213 | 04-15-2024 |
$9.8 | $9.9 | $9.8 | $10.02 | $9.595 | 318,269 | 04-12-2024 |
$10 | $10.19 | $10 | $10.27 | $9.755 | 376,079 | 04-11-2024 |
$10 | $10.37 | $10 | $10.53 | $9.904 | 739,621 | 04-10-2024 |
$10.67 | $10.89 | $10.67 | $10.93 | $10.43 | 1,160,058 | 04-09-2024 |
$10.75 | $11.05 | $10.75 | $11.0689 | $10.46 | 502,984 | 04-08-2024 |
$10.97 | $11.13 | $10.97 | $11.38 | $10.91 | 352,610 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...